Skip to main content
Home Home
  • Learn
    • TraceLink
    • Opus Platform
    • Agile supply chain
    • Customers
    • Partners
    • TraceLink University
    • Support
    • About Us
  • Share
    • Catalog
    • Community
    • Events
Home Home

Network

  • All Networks
    • More coming soon
  • Team
  • Process
    • Log in
      • TraceLink Classic

        app.tracelink.com

Agile Supply Chain

  • The Agile Imperative
  • Insights
  • Resources
Back
  • PDF
  • Share
    • LinkedIn
    • Twitter
    • Facebook
    • Mail

The Obstacles to End-to-End Visibility in the Pharma Supply Chain

Subscribe to Agile Supply Chain Insights

 

Thank you for contacting us; we’ll be in touch shortly.

Subscribe to Agile Supply Chain Insights
Stay informed with the latest patient-centric agile supply chain thought leadership content.

Key Takeaways

  • One of the biggest challenges facing pharma companies today is achieving end-to-end supply chain visibility. 
  • The supply chain team needs full visibility to avoid or mitigate disruptions and ensure products are delivered to patients on time, in full. 

TraceLink Digital Transformation Strategist Roddy Martin talks about the importance of achieving end-to-end pharma supply chain visibility.

Transcript:
One of the real challenges in the transformation of the supply chain is around product visibility. 

Although we’ve tracked-and-traced and regulated the flow of a product because of regulatory requirements, we don’t necessarily have proof of unique identity and unique chain of custody of a product flowing through the supply chain.

This has traditionally been dealt with by the quality and compliance teams in an organization, not by the supply chain.

Ultimately, the supply chain needs visibility of the end-to-end flow of a product in order to ascertain where is the product on its journey from where the product is made in the network around product supply all the way into the patient’s hands.


Return to: Agile Supply Chain Insights

Digital Transformation Strategies,
Industry Perspectives
Related Content
Are Data Silos Hindering Your Supply Chain Visibility? IDC Explains Why Pharma Supply Chains Need a Single Source of Truth
Traditional enterprise systems may be stifling your supply chain visibility, according to IDC. Find out what it will take to knock down the information silos.
The Path to Pharma Supply Chain Visibility: 5 Capabilities You Need to Focus on Now
Learn the five capabilities you’ll need to develop to achieve actionable, end-to-end supply chain visibility.
Infographic: 3 Keys to Supply Chain Resilience in the COVID-19 Era
See how pharma companies are responding to the pandemic and working toward building a more resilient supply chain.
  • Legal & Trust
  • Contact Us
  • Careers
  • Sitemap

© TraceLink Inc. 2009-2021 All Rights Reserved

  • Log in
    • TraceLink Classic

      app.tracelink.com

  • Legal & Trust
  • Contact Us
  • Careers
  • Sitemap